Fineline Cube

Follow:
14422 Articles
Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424
CompanyDeals

Hisun Pharma Secures China Rights to Ascentawits’ First‑In‑Class Drug AST‑3424

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices
Policy / Regulatory

Guangdong Launches 5‑Year Plan to Streamline Import of Urgently Needed Drugs and Medical Devices

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities
Company

GSK to Invest $30 B in the United States Over Five Years, Building Advanced Biopharma Facilities

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound
CompanyDrug

Novo Nordisk to File US Approval for High‑Dose Wegovy, Aiming to Match Lilly’s Zepbound

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere
CompanyDeals

Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche
CompanyDeals

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board
CompanyDeals

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio
CompanyDeals

Duoning Bio Secures Global License for Upstream Bio’s Biochemical Analyzer Portfolio

CSPC's ALMB-0166 Approved for Phase II Trials in Parkinson's Disease
Drug

CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial
CompanyDrug

Nanjing Leads Biolabs Doses First Patient in Opamtistomig Melanoma Trial

AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments
CompanyDrug

AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments

AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts
Company

AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts